PRME
New finance boss, same biotech grind
Prime Medicine said it appointed Svetlana Makhni as chief financial officer on April 16, 2026. She’s stepping into the role with a pretty classic biotech CFO backpack: financial operations, investor relations, FP&A, and corporate development.
Why this matters
CFO changes can feel like corporate furniture moving around — until you remember biotech companies live and die on cash discipline, fundraising credibility, and how well they tell the market their story. If you own the stock, you’re not just buying the science. You’re buying the team that has to keep the science funded.
The investor angle
A new CFO can signal a few things:
- the company is gearing up for more strategic financing or BD activity
- management wants a fresh voice on capital allocation
- investors will be watching for any shift in tone around runway, spending, and deal-making
No, this isn’t a revenue beat or a miracle trial readout. But for a development-stage biotech, a finance leadership change can still matter because it shapes how efficiently the company can keep the lights on while it hunts for the next breakthrough.
Big picture: sometimes the most important biotech news is who gets handed the calculator.